Since AT-III levels are low in COVID-19 patients, it has been hypothesized that antithrombin III from CCP reduces the thrombotic risk in COVID-19 [26], but this has never been formally proven and no randomized controlled trial to date has reported a reduction in thrombotic events in the CCP arm;. Here, SERPINC1 is linked to COVID-19.